PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture

被引：44
作者：
Lara H.H. [1 ]
Ixtepan-Turrent L. [1 ]
Garza-Treviño E.N. [1 ]
Rodriguez-Padilla C. [1 ]
机构：
[1] Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolas de los Garza
来源：
Journal of Nanobiotechnology | / 8卷 / 1期
关键词：
Human Immunodeficiency Virus; Silver Nanoparticles; Human Immunodeficiency Virus Infection; Cervical Tissue; Cervical Explant;
D O I：
10.1186/1477-3155-8-15
中图分类号：
学科分类号：
摘要：
Background: Previous in vitro studies have demonstrated that polyvinylpyrrolidone coated silver nanoparticles (PVP-coated AgNPs) have antiviral activity against HIV-1 at non-cytotoxic concentrations. These particles also demonstrate broad spectrum virucidal activity by preventing the interaction of HIV-1 gp120 and cellular CD4, thereby inhibiting fusion or entry of the virus into the host cell. In this study, we evaluated the antiviral activity of PVP-coated AgNPs as a potential topical vaginal microbicide to prevent transmission of HIV-1 infection using human cervical culture, an in vitro model that simulates in vivo conditions.Results: When formulated into a non-spermicidal gel (Replens) at a concentration of 0.15 mg/mL, PVP-coated AgNPs prevented the transmission of cell-associated HIV-1 and cell-free HIV-1 isolates. Importantly, PVP-coated AgNPs were not toxic to the explant, even when the cervical tissues were exposed continuously to 0.15 mg/mL of PVP-coated AgNPs for 48 h. Only 1 min of PVP-coated AgNPs pretreatment to the explant was required to prevent transmission of HIV-1. Pre-treatment of the cervical explant with 0.15 mg/mL PVP-coated AgNPs for 20 min followed by extensive washing prevented the transmission of HIV-1 in this model for 48 h.Conclusions: A formulation of PVP-coated AgNPs homogenized in Replens gel acts rapidly to inhibit HIV-1 transmission after 1 min and offers long-lasting protection of the cervical tissue from infection for 48 h, with no evidence of cytotoxicity observed in the explants.Based on this data, PVP-coated AgNPs are a promising microbicidal candidate for use in topical vaginal/cervical agents to prevent HIV-1 transmission, and further research is warranted. © 2010 Lara et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 77 条
  • [1] Ray N., Maraviroc in the treatment of HIV infection, Drug Des Devel Ther, 2, pp. 151-161, (2009)
  • [2] Walker P.R., Worobey M., Rambaut A., Holmes E.C., Pybus O.G., Epidemiology: Sexual transmission of HIV in Africa, Nature, 422, (2003)
  • [3] Elias C., Coggins C., Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?, J Womens Health Gend Based Med, 10, pp. 163-173, (2001)
  • [4] Kalichman S.C., Williams E.A., Cherry C., Belcher L., Nachimson D., Sexual coercion, domestic violence, and negotiating condom use among low-income African American women, J Womens Health, 7, pp. 371-378, (1998)
  • [5] van der Straten A., King R., Grinstead O., Serufilira A., Allen S., Couple communication, sexual coercion and HIV risk reduction in Kigali, Rwanda, AIDS, 9, pp. 935-944, (1995)
  • [6] Balzarini J., Naesens L., Verbeken E., Laga M., Van D.L., Parniak M., Van M.L., Anne J., De C.E., Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent, AIDS, 12, pp. 1129-1138, (1998)
  • [7] McGowan I., Microbicides: a new frontier in HIV prevention, Biologicals, 34, pp. 241-255, (2006)
  • [8] Fowler M.G., Melnick S.L., Mathieson B.J., Women and HIV. Epidemiology and global overview, Obstet Gynecol Clin North Am, 24, pp. 705-729, (1997)
  • [9] Elias C.J., Coggins C., Female-controlled methods to prevent sexual transmission of HIV, AIDS, 10, SUPPL 3, (1996)
  • [10] Brown H., Marvellous microbicides. Intravaginal gels could save millions of lives, but first someone has to prove that they work, Lancet, 363, pp. 1042-1043, (2004)
12345678